

Receipt date: 05/24/2013

13901830 - GAU: 1628

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>			
				Application Number			
				Filing Date			
				First Named Inventor		Giorgio Calderari	
				Art Unit			
				Examiner Name			
Sheet	1	of	12	Attorney Docket Number	23278.2.US.9		

U.S. PATENTS					
Examiner Initials	Cite No. <sup>1</sup>	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	1	US-5,272,137	12-00-1993	Blase et al.	
	2	US-4,695,578	09-22-1987	Coates et al.	
	3	US-4,753,789	06-28-1988	Tyers et al.	
	4	US-4,886,808	12-12-1989	King	
	5	US-4,906,755	03-06-1990	Gittos	
	6	US-4,929,632	05-29-1990	Tyers et al.	
	7	US-4,937,247	06-26-1990	King	
	8	US-5,011,846	04-30-1991	Gittos et al.	
	9	US-5,034,398	07-23-1991	King	
	10	US-5,240,954	08-31-1993	Tyers et al.	
	11	US-5,344,658	09-06-1994	Collin	
	12	US-5,578,628	11-26-1996	Tyers et al.	
	13	US-5,578,632	11-26-1996	Tyers et al.	
	14	US-5,622,720	04-22-1997	Collin	
	15	US-5,922,749	07-13-1997	Tyers et al.	
	16	US-5,955,488	09-21-1999	Winterborn	
	17	US-6,063,802	05-16-2000	Winterborn	
	18	US-6,294,548	09-25-2001	James	
	19	US-5,854,270	12-29-1998	Gambhir	
	20	US-5,202,333	04-13-1993	Berger et al.	
	21	US-6,287,592	09-11-2001	Dickinson	
	22	US-6,284,749	09-04-2001	Castillo et al.	
	23	US-6,132,758	10-17-2000	Farah J. Munayyer et al. (Schering Corporation)	
	24	US-6,699,852	03-02-2004	Albert Robichaud (Bristol-Myers Squibb Pharma Co.)	
	25	US-7,109,339	09-19-2006	Tackyu Lee et al. (Bristol-Myers Squibb Company)	
	26	US-7,947,724	05-14-2011	Giorgio Calderari, et al.	
	27	US-7,947,725	05-14-2011	Giorgio Calderari et al.	
	28	US-7,960,424	06-14-2011	Giorgio Calderari et al.	

5582040v1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.G./

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>			
				Application Number			
				Filing Date			
				First Named Inventor		Giorgio Calderari	
				Art Unit			
				Examiner Name			
Sheet	2	of	12	Attorney Docket Number	23278.2.US.9		

U.S. PUBLISHED PATENT APPLICATIONS						
Examiner Initials	Cite No. <sup>3</sup>	Document Number		Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>4</sup> (if known)				
	29	US-20010020029		09-06-2001	James	
	30	US-20030095926		05-22-2003	Dugger, III	

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>8</sup>
		Country Code <sup>5</sup> Number <sup>6</sup> Kind Code <sup>7</sup> (if known)					
	31	WO-2004067005		08-12-2004	Helsinn Healthcare S.A.		
	32	WO-2003100091		12-04-2003	Brockmüller		
	33	WO-2004703714		09-02-2004	Helsinn Healthcare S.A.		
	34	WO-2004045615		06-03-2004	Helsinn Healthcare S.A.		
	35	EP-0 512 400 A1		04-29-1992	Hallinan, E. Ann (G.D. Searle & Co.)		

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
	100	R. M. Eglen et al., "Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo," Br. J Pharmacology 114:860-866 (1995)	
	101	Chelly, Jacques et al., Oral RS-25259 Prevents Postoperative Nausea and Vomiting Following Laparoscopic Surgery, Anesthesiology, 1996, Vol., 85, No. 3A, p. A21	
	102	Sorbe, Bengt, 5-HT-3 Receptor Antagonists as Antiemetic Agents in Cancer Chemotherapy, extracted from Expert Opinion on Investigational Drugs, 1996, vol. 5 no. 4, pp. 389-407	
	103	Gaster, Laramie M. and King, Frank D., Serotonin 5-HT3 and 5-HT4 Receptor Antagonists, extracted from Medicinal Research Reviews, 1997 vol. 17, no. 2, pp. 163-214	
	104	Tang, Jun et al., "Efficacy of RS-25259, a Novel 5-HT3 Antagonist, In the Prevention of Postoperative Nausea and Vomiting after Major Gynecologic Surgery," Anesthesiology, 1997, vol. 85, No. 3 suppl. p. A329	
	105	Tang, Jun et al., The Efficacy of RS-25259, a Long-Acting Selective 5-HT3 Receptor Antagonist, for Preventing Postoperative Nausea and Vomiting After Hysterectomy Procedures, Anesthesia and Analgesia, 1998, vol. 87, pp. 462-467	
	106	Adis R&D Profile, Palonosetron RS 25259 197, Drugs in R&D, October 1999, vol. 2, no. 4, pp. 251-252	
	107	Piraccini Gaia et al., An Interesting 5-HT3 Receptor Antagonist Antiemetic for Patients Undergoing Chemotherapy-based Conditioning Regimens," Blood, Nov. 16, 2001, vol. 98, no. 11, part 2, p. 350b, abstract no. 5169	
	108	Stacher, Georg, Palonosetron Helsinn, Current Opinion in Investigational Drugs. October 2002, vol. 3, no. 10, pp. 1502-7	
	109	Navari, Rudolph M., Pathogenesis-Based Treatment of Chemotherapy-Induced Nausea and Vomiting - Two New Agents, Journal of Supportive Oncology, 2003, vol. 1(2), pp. 89-103	
	110	Chaitow, 1990, 3 pages	
	111	Opposition Brief filed by Dr. Reddy's Laboratories (UK) Limited, opposition to European Patent No. 1601359 B1 dated July 7, 2009	
	112	Photolytic and oxidative degradation of an antiemetic agent, RG 12915 (Won C. M. et al., International Journal of Pharmaceutics 121, 95-105 (1995)	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>		
				Application Number		
				Filing Date		
				First Named Inventor		Giorgio Calderari
				Art Unit		
Examiner Name						
Sheet	3	of	12	Attorney Docket Number	23278.2.US.9	

NONPATENT LITERATURE DOCUMENTS		
113	Palonosetron: a phase II dose ranging study to assess over a 7 day period the single dose pharmacokinetic profile of palonosetron in patients receiving highly emetogenic chemotherapy. Piraccini et al., Proc. Am. Soc. Clin. Oncol 2002 21 Abs 449 (2002)	
114	Formulation and administration techniques to minimize injection pain and tissue damage associated with parenteral products. Larry A. Gatlin and Carol A. Brister Gatlin, from Injectable Drug Development: Techniques to Reduce Pain and Irritation (Edited by Pramod K. Gupta and Gayle A. Brazeau; published by Informa Health Care) 1999; ISBN 1574910957, 9781574910957, p. 401-421	
115	Parenteral Dosage Forms. Joanne Broadhead, from Part 11-Early drug development, pharmaceutical preformulation and formulation: a practice guide from candidate drug selection to commercial dosage form (Edited by Mark Gibson; Published by Interpharma Press, 2001; ISBN 1574911201, 9781574911206), p. 331-353	
116	Opposition Brief filed by Tecnimede Sociedade Tecnico-Medicinal S.A. in opposition to European Patent No. 1601359 B1, July 8, 2009	
117	Response brief filed by Helsinn Healthcare S.A. dated July 13, 2007, in response to the communication pursuant to Art. 96(2) EPC of 3 January 2007 regarding Serial Number 04 706 657.6-2123	
118	European Patent Office official communication dated July 19, 2006, regarding Serial No. 04 706 657.6	
119	Response of Helsinn Healthcare S.A. dated November 29, 2006, regarding EPO official communication date July 19, 2006	
120	Lachman et al., The Theory and Practice of Industrial Pharmacy, 1986, third edition, pp. 652-784	
121	Declaration of Valentino J. Stella, Ph.D. dated September 19, 2007	
122	Opposition Brief filed by Martin Paul White, opposition to European Patent No. 1601359 B1, July 8, 2009	
123	Wong et al. (1995), in British Journal of Pharmacology, volume 114, pages 851-859	
124	Cover page and pages 642-644 and 783-784 of The Theory and Practice of Industrial Pharmacy, Third Edition, Lea and Febiger (1986)	
125	Cover page and pages 514-515 of Modern Pharmaceutics, Second Edition, Marcel Dekker (1990)	
126	Cover page and pages 142-143 of Pharmaceutical Dosage Forms: Parenteral Medications Volume 1, Second Edition, Marcel Dekker (1992)	
127	Mitsuo Matsumoto et al., "Yakuzaigaku Manual", 1st edition, Nanzando Co., Ltd. (1989) 2 pages	
128	Michael J. Pikal, "Freeze Drying", Encyclopedia of Pharmaceutical Technology, Third Edition, January 2007, Pages 1824-1825, Volume 3, Informa Pharmaceuticals and Healthcare	
129	Daniele Bonadeo, "Supplemental Declaration of Daniele Bonadeo Under 37 C.F.R. 1.132", filed in U.S. Patent Application Serial No. 11/388,270, June 8, 2009	
130	Kranke et al., 2007 "Recent advances, trends, and economic considerations in..." Expert Opinion Pharmacotherp., 8(18): 3217-3235	
131	Morrow et al., 1995, "Progress in reducing nausea and emesis: Comparisons of ondansetron, granisetron, and tropisetron." Cancer, Volume 76, No. 3 pages 343-357.	
132	USPTO Notice of Allowance and Fees Due, USSN 11/388,270, Filing Date 03/24/2006, Date Mailed 01/26/2010	
133	USPTO Office Action, USSN 11/129,839, Date Mailed 01/15/2010	
134	Israili, Zafar H., "Clinical Pharmacology of Serotonin Receptor Type (5-HT3) Antagonists," Curr. Med. Chem. Central Nervous System Agents, 2001:1, 171-199	
135	Barton (Citrate Buffer Calculation) 2000, 2 pages	
136	USPTO Office Action, USSN 11/201,035, Date Mailed 08/19/2009	
137	Response of Helsinn Healthcare to opposition of EP Serial No. 04 706 657.6, dated February 11, 2010	
138	Annex 1 (Statement of Walso Mossi, Ph.D.) to Response of Helsinn Healthcare to Opposition of EP Serial No. 04 706 657.6, dated February 11, 2010	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>			
				Application Number			
				Filing Date			
				First Named Inventor		Giorgio Calderari	
				Art Unit			
Examiner Name							
Sheet	4	of	12	Attorney Docket Number	23278.2.US.9		

NONPATENT LITERATURE DOCUMENTS		
139	Annex 2 to Response of Helsinn Healthcare to Opposition of EP Serial No. 04 706 657.6 dated February 11, 2010	
140	Annex 3 to Response of Helsinn Healthcare to Opposition of EP Serial No. 04 706 657.6 dated February 11, 2010	
200	Summary of Product Characteristics for Aloxi 250 (2009)	
201	Scientific Discussion from the European Public Assessment Report for Aloxi (Palonoseteron Hydrochloride) 2006	
202	6th Edition, Handbook of Pharmaceutical Excipients (2009), pp. 247-250 (RPS Publishing)	
203	Lewis, Gareth A (2006) 'Optimization Methods,' Encyclopedia of Pharmaceutical Technology, 1:1, 2452-2467	
204	May 24, 2011 Para. IV notice from Teva Pharmaceuticals re '724 and '725 patents	
205	May 24, 2011 Para. IV notice from Sandoz re '724 and '725 patents	
206	May 24, 2011 Para. IV notice from Dr. Reddy's re '724 and '725 patents	
207	Aug. 9, 2011 Para. IV notice from Dr. Reddy's re '424 patent	
208	Aug. 19, 2011 Para. IV notice from Teva Pharmaceuticals re '424 patent	
209	Sept. 22, 2011 Para. IV notice from Sandoz re '724, '725 and '424 patents	
210	July 8, 2011 Complaint for patent infringement (D. N.J. case No. 11-03962)	
211	Sept. 23, 2011 Complaint for patent infringement (D. N.J. case No. 11-5579)	
212	August 31, 2011 Answer and counterclaim of Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. (D. N.J. case No. 11-03962)	
213	Sept. 13, 2011 Sandoz Inc.'s answer to complaint for patent infringement and counterclaims (D. N.J. case No. 11-03962)	
214	Sept. 13, 2011 Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd.'s answer (D. N.J. case No. 11-03962)	
215	Oct. 5, 2011 Plaintiff's reply to answer and counterclaim of Dr. Reddy's Laboratories, Ltd. and Dr. Reddy Laboratories, Inc. (D. N.J. case No. 11-03962)	
216	Oct. 21, 2011 Plaintiff's reply to Sandoz Inc.'s answer to complaint for patent infringement and counterclaims (D. N.J. case No. 11-03962)	
217	Oct. 24, 2011 Answer and counterclaim of Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. (D. N.J. case No. 11-5579)	
218	Oct. 24, 2011 Sandoz Inc.'s answer to complaint for patent infringement and counterclaims (D. N.J. case No. 11-5579)	
219	Oct. 27, 2011 Order consolidating the two cases (D. N.J. case No. 11-5579)	
220	Nov. 17, 2011 Plaintiffs' reply to answer and counterclaim of Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. (D. N.J. case No. 11-03962)	
221	Nov. 17, 2011 Plaintiffs' reply to Sandoz Inc.'s answer to complaint for patent infringement and counterclaims (D. N.J. case No. 11-03962)	
222	Dec. 5, 2011 Teva Pharmaceuticals USA Inc. and Teva Pharmaceuticals Industries Ltd.'s answer to complaint for patent infringement of the '424 patent (D. N.J. case No. 11-03962)	
223	May 21, 2012 Defendants' opening claim construction brief (including exhibits 1-31)	
224	May 21, 2012 Plaintiffs' opening claim construction brief (including exhibits 1-15)	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>			
				Application Number			
				Filing Date			
				First Named Inventor		Giorgio Calderari	
				Art Unit			
				Examiner Name			
Sheet	5	of	12	Attorney Docket Number	23278.2.US.9		

NONPATENT LITERATURE DOCUMENTS		
225	July 20, 2012 Defendants' responsive claim construction brief (including exhibits 1-3)	
226	July 20, 2012 Plaintiffs' responsive claim construction brief (including Exhibits A and B)	
227	Sept. 7, 2012 Court transcript from September 7, 2012 Markman hearing and Plaintiffs' PowerPoint presentation (D. N.J. case No. 11-03962)	
228	Dec. 1, 2011 Sandoz Inc.'s invalidity contentions pursuant to L. Pat. R. 3.6(c) (D. N.J. case No. 11-03962)	
229	Dec. 1, 2011 Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd.'s invalidity contentions, pursuant to L. Pat. R. 3.6(c)(D. N.J. case No. 11-03962)	
230	Dec. 1, 2011 Dr. Reddy's Laboratories, Ltd.'s and Dr. Reddy's Laboratories, Inc.'s invalidity contentions pursuant to L. Pat. R. 3.6(c) (D. N.J. case No. 11-03962)	
231	Jan. 31, 2012 Plaintiff's responses to defendants' invalidity contentions (D. N.J. case No. 11-03962)	
232	Sept. 25, 2012 Sandoz Inc.'s first amended invalidity contentions pursuant to L. Pat. R. 3.6(c) (D. N.J. case No. 11-03962)	
233	Nov. 19, 2012 Plaintiffs' responses to Sandoz Inc.'s first amended invalidity contentions (D. N.J. case No. 11-03962)	
234	L.G. Wade Jr., Organic Chemistry, Ch. 19: Amines, pp. 867-936 (Prentice Hall 3d ed. 1995)	
235	L. Lachman et al., The Theory and Practice of Industrial Pharmacy, pp. 642-644, 783-784 (Lea & Febiger 3d ed. 1986)	
236	P.P. DeLuca et al., Formulation of Small Volume Parenterals in Pharmaceutical Dosage Forms: Parenteral Medications, Vol. 1, Ch. 5, pp. 173-248 (Avis, Lieberman, Lachman eds., Marcel Dekker Inc. 2d ed. 1992)	
237	C.M. Won et al, Photolytic and Oxidative Degradation of an Antiemetic Agent, RGI2915, Int'l J Pharmaceutics 121:95-105 (1995)	
238	R.D. Clark et al., 2-(Quinuclidin-3-yl)pyrido-[4,3-b]indol-1-ones and Isoquinolin-1-ones. Potent Conformationally Restricted 5-HT <sub>3</sub> Receptor Antagonists, J Med. Chem. 36:2645-57 (1993)	
239	L.A. Trissel, Drug Stability and Compatibility Issues, Handbook on Injectable Drugs, pp. XI-XVI (ASHP 7th ed. 1992)	
240	J. Broadhead, Parenteral Dosage Forms, Pharmaceutical Preformulation and Formulation: A Practical Guide from Candidate Drug Selection to Commercial Dosage Form, Ch. 9, pp. 331-54 (Gibson ed., CRC Press 1st ed. 2001)	
241	K.A. Connors et al., Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists (John Wiley & Sons 2d ed. 1986)	
242	ZOFRAN®, in The Physician's Desk Reference, op. 1503-07 (5th ed. 2001)	
243	ANZEMET®, in The Physician's Desk Reference, pp. 680-83 (5th ed. 2001)	
244	KYTRIL®, in The Physician's Desk Reference, pp. 3104-06 (5th ed. 2001)	
245	L.A. Trissel, Ondansetron HCl, in Handbook on Injectable Drugs, pp. 683-88 (ASHP 7th ed. 1992)	
246	NAVOBAN® (tropisetron HCl) Malaysian Prescribing Information (Sep. 2000)	
247	KYTRIL® (granisetron HCl) South African Prescribing Information (Dec. 1993)	
248	S. Motola and S. Agharkar, Preformulation Research of Parenteral Medications, Pharmaceutical Dosage Forms: Parenteral Medications, Vol. 1, Ch. 4, pp. 115-72 (Avis, Lieberman, Lachman eds., Marcel Dekker Inc. 2d ed. 1992)	
249	J. Wells, Pharmaceutical Preformulation: The Physicochemical Properties of Drug Substances, Ch. 5: Drug Stability, pp. 152-91 (Ellis Horwood Ltd. 1988)	
250	J. Swarbrick and Boylan, Encyclopedia of Pharmaceutical Technology, Excipients Chapter: Their Role in Parenteral Dosage Forms, Vol. 19(2):137-172 (Marcel Dekker, Inc. 2000)	
251	Handbook of Pharmaceutical Excipients, 3d Ed., (Kibbe ed. Pharmaceutical Press 2000); pp. 140-143, 191-194, 324-238	

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.